PMX 53
- Product Name
- PMX 53
- CAS No.
- 219639-75-5
- Chemical Name
- PMX 53
- Synonyms
- PMX-53 (3D53);C5aR Antagonist, PMX53;Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg);L-Arginine, N-acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-, (6→2)-lactam;(S)-N-((3R,6S,9S,15S,20aS)-6-((1H-indol-3-yl)methyl)-3-(cyclohexylmethyl)-9-(3-guanidinopropyl)-1,4,7,10,16-pentaoxoicosahydropyrrolo[1,2-a][1,4,7,10,13]pentaazacyclooctadecin-15-yl)-2-acetamido-3-phenylpropanamide
- CBNumber
- CB64796594
- Molecular Formula
- C47H65N11O7
- Formula Weight
- 896.11
- MOL File
- 219639-75-5.mol
PMX 53 Property
- Density
- 1.40±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C, protect from light, stored under nitrogen
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 13.23±0.70(Predicted)
- color
- White to off-white
- Water Solubility
- Soluble to 2 mg/ml in water
- Sequence
- Ac-Phe-{Orn}-Pro-{dCha}-Trp-Arg (Lactam bridge: Orn2-Arg6)
N-Bromosuccinimide Price
- Product number
- 5.33683
- Product name
- C5aR Antagonist, PMX53
- Packaging
- 10 mg
- Price
- $278
- Updated
- 2025/07/31
- Product number
- CS-0025111
- Product name
- PMX-53
- Purity
- 98.85%
- Packaging
- 5mg
- Price
- $450
- Updated
- 2021/12/16
- Product number
- CS-0025111
- Product name
- PMX-53
- Purity
- 98.85%
- Packaging
- 10mg
- Price
- $700
- Updated
- 2021/12/16
- Product number
- CS-0025111
- Product name
- PMX-53
- Purity
- 98.85%
- Packaging
- 1mg
- Price
- $200
- Updated
- 2021/12/16
- Product number
- DC22200
- Product name
- PMX53
- Purity
- >98%
- Packaging
- 100mg
- Price
- $1900
- Updated
- 2021/12/16
PMX 53 Chemical Properties,Usage,Production
Uses
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects[1][2][3][4][5][6].
Biological Activity
Cell permeable: yes', 'Primary Target
C5aR', 'Reversible: yes
in vivo
PMX-53 (0.3-3 mg/kg; subcutaneous injection; once; male Wistar rats) treatment inhibits the hypernociception induced by zymosan-activated serum and C5a but not by the direct-acting hypernociceptive mediators, prostaglandin E2 and dopamine[2].
Local pretreatment of rats with PMX-53 (60-180 μg per paw) inhibits zymosan-, carrageenan-, lipopolysaccharide (LPS)- and antigen-induced hypernociception[2].
Pharmacokinetic analyses have shown that PMX-53 (3D53) appears in the plasma within 5 min of oral administration (3 mg/kg) to rats, with peak blood levels of approximately 0.3 μM being reached within 20 min The plasma elimination half-life was approximately 70 min in this case[3].
The non-acetylated version of PMX-53 (3D53) binds to isolated mouse neutrophils with a Kd value of 30 nM (mouse C5a binds with a Kd value of 0.3 nM) and inhibits mouse C5a-induced chemotaxis with an IC50 value of 0.5 nM[3].
| Animal Model: | Adult male Wistar rats (weighing 180-200?g) injected with zymosan[2] |
| Dosage: | 0.3 mg/kg, 1 mg/kg or 3?mg/kg |
| Administration: | Subcutaneous injection; once |
| Result: | Inhibited the hypernociception induced by zymosan-activated serum and C5a. |
storage
Store at -20°C
References
[1] Subramanian H, et al. PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells. Mol Pharmacol. 2011 Jun;79(6):1005-13. DOI:10.1124/mol.111.071472
[2] Ting E, et al. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol. 2008 Mar;153(5):1043-53. DOI:10.1038/sj.bjp.0707640
[3] Holland MC, et al. Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs. 2004 Nov;5(11):1164-73. PMID:15573867
[4] Finch AM, et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem. 1999 Jun 3;42(11):1965-74. DOI:10.1021/jm9806594
[5] Manthey HD, et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011 Jul;25(7):2447-55. DOI:10.1096/fj.10-174284
[6] Vadrevu SK, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 2014 Jul 1;74(13):3454-65. DOI:10.1158/0008-5472.CAN-14-0157
PMX 53 Preparation Products And Raw materials
Raw materials
Preparation Products
PMX 53 Suppliers
- Tel
- 025-83697070
- Fax
- +86-25-83453306
- info@chemlin.com.cn
- Country
- China
- ProdList
- 15883
- Advantage
- 64
- Tel
- 0731-85526065 13308475853
- ivy@hnhbsj.com
- Country
- China
- ProdList
- 7247
- Advantage
- 62
- Tel
- 0571-87396432
- Fax
- 0571-87396431
- sales@jhechem.com
- Country
- China
- ProdList
- 14912
- Advantage
- 59
- Tel
- info@creative-peptides.com
- Country
- United States
- ProdList
- 6083
- Advantage
- 56
- Tel
- 021-QQ：65489617 15618227136
- Fax
- 21-5161 9052
- Sales@ATKchemical.com
- Country
- China
- ProdList
- 9119
- Advantage
- 58
- Tel
- 010-50973130 18101056239
- 3193328036@qq.com
- Country
- China
- ProdList
- 29760
- Advantage
- 68
- Tel
- 0571-87213919
- Eric@peptidego.com
- Country
- China
- ProdList
- 7408
- Advantage
- 58
- Tel
- 400-9205774
- sales@glpbio.cn
- Country
- China
- ProdList
- 6777
- Advantage
- 58
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-2135480471
- sales@sarms4muscle.com
- Country
- China
- ProdList
- 10473
- Advantage
- 58